89bio, Inc.
ETNBDelisted Oct 30, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785173
89bio, Inc. was delisted on Oct 30, 2025; its insiders filed their last Form 4 on Nov 3, 2025; 198 institutions reported holding it in 13F filings for Q3 2025, worth $2.27B in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 198
- Q3 2025, +15 vs. previous quarter
- 13F value
- $2.27B
- Reported value at the end of Q3 2025
- Superinvestors holding
- 0
- At the end of Q3 2025
Superinvestors holding ETNB, Q3 2025
No superinvestor reported holding ETNB at the end of Q3 2025.
Latest insider trades
Open-market purchases and sales by 89bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 17, 2025 (view filing) | Jul 15 | 2 days | Le-Nguyen QuocSee Remarks | SSale | −10.5K | $11.02 | −$115.3K | −3.3%309.4K after | 10b5-1 |
| Apr 17, 2025 (view filing) | Apr 15 | 2 days | Le-Nguyen QuocSee Remarks | SSale | −15.3K | $5.95 | −$91.2K | −4.5%328.3K after | 10b5-1 |
| Feb 3, 2025 (view filing)5:38 PM ET | Jan 30 | 4 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchase | +5.71M | $8.75 | +$50.0M | +41.3%19.6M after | |
| Jan 23, 2025 (view filing) | Jan 21-22 | 2 days | McWherter CharlesDirector | PPurchase | +15.0K | $6.66 | +$99.8K | +150.0%25.0K after | 2 lots |
| Jan 17, 2025 (view filing) | Jan 15 | 2 days | Le-Nguyen QuocSee Remarks | SSale | −11.0K | $6.49 | −$71.1K | −3.9%271.8K after | 10b5-1 |
| Dec 10, 2024 (view filing) | Dec 6 | 4 days | Palekar RohanChief Executive Officer | PPurchase | +5.00K | $7.89 | +$39.5K | +1.1%471.2K after | |
| Dec 9, 2024 (view filing) | Dec 5 | 4 days | McWherter CharlesDirector | PPurchase | +10.0K | $8.00 | +$80.0K | New position10.0K after | |
| Nov 25, 2024 (view filing) | Nov 22 | 3 days | Palekar RohanChief Executive Officer | PPurchase | +10.0K | $8.35 | +$83.5K | +2.2%466.2K after | |
| Nov 18, 2024 (view filing)8:13 PM ET | Nov 14 | 4 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchase | +3.25M | $8.50 | +$27.6M | –4.33M after | Derivative |
| Nov 1, 2024 (view filing) | Oct 30 | 2 days | Le-Nguyen QuocSee Remarks | SSale | −28.0K | $8.12 | −$227.0K | −13.0%187.8K after | 10b5-1 |
Top 10 13F holders, Q3 2025
The largest institutional positions in 89bio, Inc. at the end of Q3 2025; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 19,889,683 | $292.4M | 3.60% | 00.0% | Unchanged |
| Pentwater Capital Management LP | 11,750,000 | $172.7M | 1.55% | +11,750,000 | New |
| BlackRock, Inc. | 10,316,393 | $151.7M | 0.00% | −253,031−2.4% | Reduced |
| Deep Track Capital, LP | 9,356,171 | $137.5M | 3.84% | −143,829−1.5% | Reduced |
| Adage Capital Partners GP, L.L.C. | 9,097,587 | $133.7M | 0.21% | +7,128,587+362.0% | Added |
| Suvretta Capital Management, LLC | 8,280,000 | $121.7M | 3.69% | −5,930,000−41.7% | Reduced |
| Vanguard Group Inc | 8,053,459 | $118.4M | 0.00% | −188,695−2.3% | Reduced |
| Avoro Capital Advisors LLC | 6,387,790 | $93.9M | 1.21% | −362,210−5.4% | Reduced |
| Glazer Capital, LLC | 5,636,905 | $82.9M | 2.78% | +5,636,905 | New |
| Janus Henderson Group PLC | 5,378,185 | $79.1M | 0.04% | −15,410,178−74.1% | Reduced |